Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications. [PDF]
Curr Ther Res Clin ExpYu J +4 more
europepmc +1 more source
Genetic variants of CYP2C9 and VKORC1 in patients with LVAD
, 2017 Saule Rakhimova +4 more
openalex +1 more source
Knockdown of RNA editing proteins reshapes the HepaRG transcriptome and pharmacogene expression. [PDF]
Sci RepCollins JM, Yu F, Zhang Y, Wang D.
europepmc +1 more source
Beyond the Very Important Pharmacogenes (VIPs): Uncovering Shadow Pharmacogenes in the Human Drug Response Network. [PDF]
ACS Omegade Melo NC +5 more
europepmc +1 more source
<i>CYP2C9</i> polymorphism is associated with susceptibility to ischemic stroke in a Chinese population. [PDF]
Ann MedZhang J +5 more
europepmc +1 more source
Retraction Note: Identification of the Effects of Pathogenic Genetic Variations of Human CYP2C9 and CYP2D6: An In Silico Approach [PDF]
Orçun Avşar
openalex +1 more source
Prevalence of risk phenotypes associated with <i>CYP2C9*2, *3,</i> and <i>VKORC1 c.-1639G>A</i> genetic polymorphisms in world populations: implications in clinical practice. [PDF]
Front PharmacolBiswas M +6 more
europepmc +1 more source
Protein Levels of 16 Cytochrome P450s and 2 Carboxyl Esterases Using Absolute Quantitative Proteomics: CYP2C9 and CYP3A4 Are the Most Abundant Isoforms in Human Liver and Intestine, Respectively. [PDF]
Pharmaceuticals (Basel)Grangeon A +5 more
europepmc +1 more source
Repeated Intake of Grapefruit Juice Inhibits CYP2B6, CYP2C9, CYP2C19, and CYP3A4 while Lingonberry Powder Does Not Induce Major CYP Enzymes in Humans. [PDF]
Clin Pharmacol TherAurinsalo L +7 more
europepmc +1 more source